RORZE CORPORATION
6323・Prime Market・Machinery
Business
Rorze Corporation is a semiconductor & FPD related equipment manufacturer founded in 1985, forming a group that includes 14 consolidated subsidiaries. Its core business is the development, manufacturing, and sale of cleanroom transfer systems—including EFEM (Atmospheric Wafer Transfer System), Wafer Sorter, and N₂ Purge-Compatible Wafer Stocker—used in the front-end semiconductor manufacturing process, accounting for approximately 99% of net sales. Major customers include semiconductor manufacturing equipment makers such as Applied Materials, Inc. (19.3% of net sales for FY2025 (ended February 2025)) and major foundries. The company has established a global support structure with locations in Taiwan, South Korea, the United States, China, Vietnam, Singapore, and Germany. In its Life Science Business, the company offers Incubators (Cell Culture Equipment) for drug discovery and cell culture applications, aiming for future diversification.
Business Model
Build-to-order equipment sales tailored to customer specifications form the core of revenue, with orders received in FY2025 (ended February 2025) reaching ¥110,081 million (123.3% year-on-year). The company maintains cost competitiveness with its Vietnamese subsidiary as its main manufacturing base, while enhancing customer satisfaction through rapid support from its bases in various countries. In addition, sales of parts, repairs, and other items expanded to ¥8,943 million (up 143.0% year-on-year), and aftermarket revenue generated after equipment installation is beginning to function as a stable revenue source.
Company Strengths
Atmospheric wafer transfer systems such as EFEM (Atmospheric Wafer Transfer System) and Wafer Sorter are supplied to Applied Materials at an annual value of ¥24,018 million (19.3% of net sales), demonstrating a track record of adoption by top global equipment manufacturers. Development of next-generation products such as EUV reticle stockers and sorters equipped with camera-mounted robots is also continuing.
The operating margin for FY2025 (ending February 2025) remained at a high level of 25.7% (operating profit of ¥32,024 million on net sales of ¥124,406 million). Having consistently secured a margin above 25% since 23.6% in FY2022 (ending February 2022), the efficient production system leveraging the Vietnam base and the global sales network underpin the high profit margin.
As of the end of FY2025 (ending February 2025), the equity ratio was 62.8% (improved from 59.1% in the previous period), and against cash and cash equivalents of ¥61,330 million, interest-bearing debt stood at ¥31,614 million, maintaining a substantial net cash position. Operating cash flow improved significantly to ¥36,791 million from ¥15,544 million in the previous period, reflecting a high degree of financial stability.
ENVALITH's Perspective
Performance Trend
Revenue over the past five fiscal periods has generally expanded: ¥67,004 million in FY2022 → ¥94,518 million in FY2023 → ¥93,247 million in FY2024 → ¥124,406 million in FY2025 → ¥128,794 million in FY2026 (ending Feb 2026). In FY2026 (ending March 2026), revenue increased but operating profit declined to ¥31,154 million (down 2.7% year on year), marking a shift to lower profit. However, in Q1 of FY2027 (ending Feb 2027), revenue reached ¥37,206 million (up 12.5% year on year), operating profit reached ¥10,230 million (up 21.2% year on year), and the operating margin clearly improved to 27.5%. External factors—accelerating semiconductor investment for data centers driven by expanding generative AI demand, and the effect of yen depreciation—have boosted performance. The full-year forecast (revenue of ¥159,021 million, operating profit of ¥38,112 million) anticipates high growth of 23.5% and 22.3% year on year, respectively.
Growth Strategy
Building a foundation for sustainable growth around three pillars: strengthening technological capabilities, expanding production capacity, and enhancing global support
Advancing construction of a new plant at Vietnamese subsidiary RORZE ROBOTECH CO., LTD. Operations are scheduled to begin in spring 2028, with the aim of securing supply capacity to meet rapidly increasing orders (order backlog of ¥68,736 million as of Q1 FY2027 (ending February 2027)). This is also expected to contribute to improved production cost competitiveness.
Orders for analysis equipment in Q1 FY2027 (ending February 2027) reached ¥2,366 million (up 396.3% year on year), with an order backlog of ¥4,672 million (up 134.1% year on year), showing rapid expansion. Against a backdrop of growing quality control needs in advanced semiconductor processes, this business is being cultivated as a second pillar of profitability alongside transfer systems.
The Incubator (Cell Culture Equipment) business for drug discovery and cell culture applications recorded net sales of ¥131 million in Q1 FY2027 (ending February 2027) (up 18.8% year on year), with orders surging to ¥741 million (up 502.8% year on year). While a segment loss of ¥119 million continues, an order backlog of ¥772 million (up 539.1% year on year) suggests future sales contribution, indicating that a turning point toward profitability is approaching.
Sales to Applied Materials expanded rapidly to ¥8,130 million in Q1 FY2027 (ending February 2027) (up 60.7% year on year, 21.9% of net sales composition). Sales to the US also grew to become the largest regional market at ¥11,068 million (up 34.9% year on year). The company is accelerating its capture of demand for equipment used in advanced logic and memory applications.
Last updated: July 17, 2026